Breaking Down Longmaster Information & Technology Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Longmaster Information & Technology Co., Ltd. (300288.SZ) is a hidden opportunity or a turnaround story? Peek into the hard numbers: in 2024 the company posted revenue of CNY 379 million (slightly above CNY 346.87 million in 2023) while reporting a striking net loss of CNY 512 million and a diluted EPS of -CNY 1.52, even as operating cash flow stayed positive at CNY 48 million and free cash flow reached CNY 32.81 million; Longmaster entered 2025 with stronger gross margins - up to 26% from 22% - after shifting away from lower-margin electronic products, and retains a conservative balance sheet with CNY 284 million in cash and only CNY 2 million in debt, supporting a market capitalization of CNY 4.80 billion (enterprise value CNY 4.55 billion) as of October 2025; historical segment data show sizable footprints - IT consulting ≈ ¥1.5 billion, healthcare data management ≈ ¥800 million, and EHR ≈ ¥700 million with ~20% market share in 2022 - while liquidity ratios (current ratio 1.5, quick ratio 1.2), capex of CNY 15 million, and financing cash outflows of -CNY 52.9 million paint a nuanced picture of risk and runway amid intense competition, regulatory exposure, and growth avenues in telemedicine, AI R&D, licensing and e-commerce that merit a deeper read.

Longmaster Information & Technology Co., Ltd. (300288.SZ) Revenue Analysis

• 2024 reported revenue: CNY 379.0 million (company disclosure).
• 2023 reported revenue: CNY 346.87 million (company disclosure).
• Primary revenue engines: telemedicine consultations (service fees), platform licensing, hardware/electronic product sales, and healthcare e-commerce.
• 2025 directional change: reduced sales of lower-margin electronic products as the company shifts to higher‑gross‑margin offerings.

• IT consulting services: ~¥1.5 billion revenue; high profit margins >30%.
• Healthcare data management solutions: ~¥800 million revenue; margins ≈25%.
• Electronic Health Record (EHR) systems: ~¥700 million revenue; ~20% market share in its addressable market.

• Revenue model diversification reduces single-source concentration risk: recurring platform/license fees + transactional e-commerce + hardware turn-key solutions.
• Segment-level margins indicate service/platform businesses (IT consulting, data mgmt, EHR) are primary profitability drivers versus commoditized electronic product sales.
• Investors should note: reported headline revenue items across years and segments reflect both scale in services (billions in 2022 segments) and a smaller consolidated revenue figure reported for 2023-2024, requiring reconciliation in filings and segment reporting.

Longmaster Information & Technology Co., Ltd. (300288.SZ) - Profitability Metrics

This chapter focuses on key profitability indicators and cash flow dynamics for Longmaster Information & Technology Co., Ltd. (300288.SZ), highlighting recent year-on-year shifts and implications for operational resilience.

• Net result: 2024 net loss of CNY 512.0 million vs. 2023 net income of CNY 77.46 million.
• Diluted EPS (2024): -CNY 1.52 per share.
• Gross profit margin: improved to 26% in 2025 from 22% in 2024, driven primarily by higher-margin software product mix.
• Operating cash flow (2024): positive CNY 48.0 million, indicating some underlying operational cash generation despite accounting losses.
• Capital expenditures (2024): CNY 15.0 million, reflecting moderate ongoing investment in infrastructure and capacity.

Key interpretive points:

• The swing from a positive net income in 2023 to a substantial loss in 2024 (-CNY 512m) is a material red flag for profitability and warrants scrutiny of non-recurring charges, impairment events, and margin pressure earlier in 2024.
• Despite the accounting loss, positive operating cash flow of CNY 48m in 2024 signals that core operations generated cash-however, this cash flow is far below the scale of the net loss and does not offset accumulated deficits.
• An improving gross margin to 26% in 2025 suggests successful product mix shift toward higher-margin software offerings, which could support future margin recovery if sustained.
• Relatively modest capex (CNY 15m in 2024) indicates limited near-term cash drain for expansion, but also suggests constrained investment intensity.

For additional context on strategic direction that may affect future profitability, see Mission Statement, Vision, & Core Values (2026) of Longmaster Information & Technology Co., Ltd.

Longmaster Information & Technology Co., Ltd. (300288.SZ) - Debt vs. Equity Structure

• Debt level (2024): CNY 2 million - effectively minimal leverage.
• Cash & equivalents (2024): CNY 284 million - liquidity buffer against losses.
• Market capitalization (Oct 2025): CNY 4.80 billion - equity market valuation.
• Enterprise value (Oct 2025): CNY 4.55 billion - total operating-asset valuation.
• Debt-to-equity ratio: Low - indicates prudent financial management and reduced financial risk.

• Implication for investors: low balance-sheet risk from financing; primary risks remain operational and profitability-related.
• Strategic flexibility: able to fund near-term needs internally or pursue acquisitions without immediate reliance on external debt markets.

Longmaster Information & Technology Co., Ltd. (300288.SZ) - Liquidity and Solvency

• Current ratio (2024): 1.5 - adequate short-term liquidity to cover current liabilities.
• Quick ratio (2024): 1.2 - sufficient liquid assets to meet immediate obligations without relying on inventory sales.
• Operating cash flow (2024): CNY 48.0 million - positive cash generation from core operations.
• Free cash flow (2024): CNY 32.81 million - additional liquidity for investments, buybacks or debt reduction.
• Cash flow from financing activities (2024): CNY -52.9 million - net cash outflows, indicating debt repayment, dividends, or share repurchases exceeding financing inflows.

• Net liquidity picture: positive operating and free cash flows support short-term obligations and provide optionality for investments or deleveraging.
• Financing outflows warrant monitoring - if sustained, they may pressure reserves unless matched by continuing operating cash generation.

Longmaster Information & Technology Co., Ltd. (300288.SZ) - Valuation Analysis

Key valuation markers for Longmaster Information & Technology as of October 9-October 2025 highlight a company trading under loss-making conditions but with a market-implied equity value and enterprise value that invite alternative valuation approaches.

• P/E ratio: Not applicable - net loss in 2024.
• Forward P/E: Not applicable - ongoing profitability challenges expected near-term.
• Stock price (Oct 9, 2025): CNY 14.18 per share.
• Market capitalization (Oct 2025): CNY 4.80 billion.
• Enterprise value (Oct 2025): CNY 4.55 billion.
• Implied net cash position (Market cap - EV): approximately CNY 0.25 billion (250 million), suggesting net cash on the balance sheet.

Given the absence of meaningful P/E multiples, investors typically pivot to alternative metrics and qualitative assessment. Relevant approaches include:

• EV/Revenue and EV/EBITDA (if positive EBITDA) to value operating assets independent of capital structure.
• Price-to-book (P/B) and tangible book value per share to assess downside under liquidation or recovery scenarios.
• Revenue growth, gross margin trends, and cash runway to gauge when traditional earnings multiples might become relevant again.
• Balance sheet metrics (net cash of ~CNY 250m) to assess buffer vs. operating losses and working capital needs.

For company mission and strategic context that may influence valuation recovery prospects, see Mission Statement, Vision, & Core Values (2026) of Longmaster Information & Technology Co., Ltd.

Longmaster Information & Technology Co., Ltd. (300288.SZ) - Risk Factors

Longmaster Information & Technology Co., Ltd. operates at the intersection of digital healthcare, telemedicine, e‑commerce and legacy electronic product sales. The company's strategy and financial profile create several measurable risk exposures investors should weigh.

• Competitive pressure: Large technology firms (BAT/ByteDance) and specialized healthcare platforms (Ping An Good Doctor, WeDoctor equivalents) compete on user acquisition, data, and capital - pressuring margins and market share.
• Scale disadvantage: Longmaster's scale lags major incumbents, constraining bargaining power for licensing, platform partnerships and advertising monetization; smaller scale can translate into lower operating leverage and delayed profitability.
• Capital intensity of hybrid model: Integrating physical hospital assets and digital services demands heavy CAPEX and working capital to digitize operations, train clinicians, and maintain regulatory compliance.
• Regulatory/compliance exposure: Telemedicine, online prescriptions and e‑commerce of medical devices are subject to evolving PRC healthcare regulations; adverse policy shifts can curtail product offerings or require costly operational changes.
• Strategic shift impacts: Management's pivot away from electronic hardware has led to a material decline in electronic product sales, impacting near‑term revenue and requiring reallocation of sales, marketing and logistics investments.
• Revenue concentration risk: Dependence on a handful of segments (telemedicine consults, platform transaction fees, and a small set of e‑commerce categories) makes revenue volatile to demand cycles or reimbursement changes.

Specific operational and market risks derive from the above profile. Key considerations for investors include capital runway, margin trajectory as scale increases (or fails to), regulatory developments in PRC telemedicine and prescription rules, and the company's ability to diversify revenue beyond a few core segments.

• Possible short-term outcomes: need for equity or debt financing if negative OCF persists; further contraction of electronics revenue if strategic pivot continues.
• Medium-term execution risks: successfully integrating hospitals and clinicians into a digital-first platform while maintaining clinical quality and regulatory compliance.
• Downside triggers to monitor: adverse regulatory announcements, loss of major partnerships, accelerated decline in legacy product sales, or inability to secure financing on reasonable terms.

For additional investor context and shareholder activity, see: Exploring Longmaster Information & Technology Co., Ltd. Investor Profile: Who's Buying and Why?

Longmaster Information & Technology Co., Ltd. (300288.SZ) - Growth Opportunities

• Diversified revenue streams: telemedicine, technology licensing, hardware sales and e‑commerce create parallel growth channels and reduce reliance on any single business line.
• Shift to higher‑margin software: expanding subscription, SaaS and licensing revenues can materially lift gross and operating margins versus hardware sales.
• Medical AI R&D: sustained investment in algorithm development, regulatory approvals and clinical validation can enable proprietary products with pricing power.
• Regional expansion: targeting underserved second‑ and third‑tier cities in China can capture unmet demand and improve customer acquisition economics.
• Strategic partnerships: alliances with large hospitals, health groups and technology vendors can accelerate distribution, clinical acceptance and data access.
• Market tailwinds: accelerating adoption of digital health in China supports higher TAM and faster uptake of Longmaster's integrated offerings.

• Revenue mix shift: target software/SaaS share rising from current levels toward >30-40% of total revenue.
• EBITDA margin expansion: achievable improvement of 5-10 percentage points as software mix increases and device manufacturing scales.
• R&D intensity: R&D spend of 8-12% of revenue to support medical AI pipelines and regulatory work.
• Recurring revenue ratio: aim for recurring (subscription/contract) revenues >45% of total within 3 years.
• Customer penetration: growth in active hospital/clinic contracts and ARPU (average revenue per user) for platform customers by double digits annually.

• Digital health adoption: China's digital health penetration continues to accelerate, with telemedicine and remote monitoring adoption rates expanding in both public and private healthcare sectors.
• AI in healthcare: demand for AI‑enabled diagnostics and workflow tools is growing among hospitals seeking efficiency and improved clinical outcomes.
• Regulatory environment: clearer pathways for medical device and software approvals can shorten time‑to‑market for validated solutions.

• Product focus: prioritize high‑margin software modules and subscription models while optimizing device cost structures.
• R&D governance: stage‑gate investments to advance clinically validated AI products with clear commercialization plans.
• Sales motion: strengthen enterprise sales, channel partnerships and localized field teams for penetration in underserved regions.
• Data strategy: establish compliant data partnerships and commercialization frameworks to unlock analytics revenues.